Article Text

PDF
THU0539 Sarcoidosis in spain: clinical and epidemiological characteristics at diagnosis in 1082 patients
  1. R Pérez-Alvarez1,
  2. B Kostov2,
  3. A García González3,
  4. R Gόmez De La Torre4,
  5. M Lopez Dupla5,
  6. B De Escalante6,
  7. A Alguacil7,
  8. J Chara8,
  9. J Velilla9,
  10. J Rascόn10,
  11. JS Garcia Morillo11,
  12. C Feijoo12,
  13. E Fonseca13,
  14. M Bonet14,
  15. JL Callejas15,
  16. G de la Red16,
  17. E Calvo17,
  18. C Soler18,
  19. E Peral19,
  20. JF Gόmez Cerezo20,
  21. G Cruz-Caparrόs21,
  22. P Perez22,
  23. S Fernández Rodríguez23,
  24. B Pinilla24,
  25. A Gato25,
  26. M Akasbi26,
  27. A Robles27,
  28. I Ojeda28,
  29. MJ Vives29,
  30. C Morcillo30,
  31. M Penadés31,
  32. M De Vicente32,
  33. M Ramos-Casals33,
  34. L Pallarés10,
  35. P Brito-Zerόn30,33,
  36. on behalf of the SARCOGEAS-SEMI Registry
  1. 1Hosp Alvaro Cunqueiro, Vigo
  2. 2IDIBAPS, Barcelona
  3. 3Hosp Ramόn y Cajal, Madrid
  4. 4HUCA, Oviedo
  5. 5Hosp Joan XXIII, Tarragona
  6. 6Hosp Clínico, Zaragoza
  7. 7Hosp Virgen de la Salud, Toledo
  8. 8Hosp Josep Trueta, Girona
  9. 9Hosp Miguel Servet, Zaragoza
  10. 10Hosp Son Espases, Palma de Mallorca
  11. 11Hosp Virgen del Rocio, Sevilla
  12. 12Hosp Parc Taulí, Sabadell
  13. 13Hosp de Cabueñes, Gijόn
  14. 14Althaia, Manresa
  15. 15Hosp San Cecilio, Granada
  16. 16Hosp Esperit Sant, Santa Coloma
  17. 17Hosp General San Jorge, Huesca
  18. 18Hosp de Sta Caterina, Girona
  19. 19Hosp Virgen Macarena, Sevilla
  20. 20Hosp Infanta Sofía, Madrid
  21. 21Hosp de Poniente, Almería
  22. 22Hosp Puerta del Mar, Cádiz
  23. 23Hosp da Barbanza, A Coruña
  24. 24Hosp Gregorio Marañόn, Madrid
  25. 25CH, Albacete
  26. 26Hosp Infanta Leonor
  27. 27Hosp la Paz, Madrid
  28. 28Hosp Valle del Guadiato, Cόrdoba
  29. 29San Joan de Déu, San Boi
  30. 30Hosp CIMA-Sanitas, Barcelona
  31. 31Hosp de Manises, Valencia
  32. 32Hosp Nuestra Señora del Prado, Talavera
  33. 33Hosp Clínic, Barcelona, Spain

Abstract

Objectives To characterize the main features at presentation of sarcoidosis in a large multicenter cohort from Southern Europe.

Methods In January 2016, the Autoimmune Diseases Study Group (GEAS-SEMI) created a national registry (SARCOGEAS) of patients with sarcoidosis. Sarcoidosis was diagnosed in agreement with the criteria proposed by the ATS/ERS/WASOG 1999 statement, and extrathoracic disease was classified with the 2014 WASOG instrument.

Results The cohort consisted of 1082 patients (82% biopsy-proven), including 618 (57%) women and 464 (43%) men, with a mean age at diagnosis of 47yrs; 140 (13%) patients were born outside Spain, 965 (89%) were White, 69 (6%) Hispanic, 30 (3%) Black/African American and 18 (2%) Asian. Thoracic involvement was present at diagnosis in 979 (90%) patients, including 437 (40%) patients with stage I, 374 (35%) with stage II, 123 (11%) with stage III and 26 (2%) with stage IV. The most frequently reported extrathoracic involvements at diagnosis were cutaneous in 385 (36%) patients, extrathoracic lymph nodes in 218 (20%), liver involvement in 151 (14%) and ocular involvement in 118 (11%). Potentially life-threatening WASOG involvements were reported in frequencies less than 10%, including neurological involvement in 77 (7%) patients, kidney involvement in 59 (5%) or cardiac involvement in 21 (2%). Therapeutic approaches at diagnosis included the use of oral glucocorticosteroids in 637 (59%) patients, immunosuppressive agents in 84 (8%, mainly methotrexate in 63 patients) and biological agents in 15 (1%, mainly infliximab in 10 cases).

Conclusions In this large series of sarcoidosis from Southern Europe, clinical presentation is dominated by adenopathies (both thoracic and extrathoracic) and cutaneous involvement (erythema nodosum), with lower frequencies in the main extrathoracic involvements than that reported in US and Japanese series.

Disclosure of Interest None declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.